Genprex, Inc. (NASDAQ:GNPX – Free Report) – HC Wainwright boosted their Q1 2024 earnings per share estimates for Genprex in a note issued to investors on Wednesday, April 3rd. HC Wainwright analyst Y. Chen now expects that the company will earn ($2.54) per share for the quarter, up from their previous estimate of ($3.37). HC […]
Genprex, Inc. (GNPX) reported that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the non-viral Oncoprex Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer in a humanized mouse model.
HC Wainwright assumed coverage on shares of Genprex (NASDAQ:GNPX – Free Report) in a report issued on Monday morning, Benzinga reports. The firm issued a buy rating and a $10.00 price objective on the stock. Genprex Stock Down 2.0 % NASDAQ GNPX opened at $3.00 on Monday. The stock’s 50-day simple moving average is $5.55 […]
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.
/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.